Memantine has demonstrated efficacy in suppressing premature atrial contractions in a phase II trial. The study showed a reduction in both atrial ectopy and overall atrial tachyarrhythmia ...
BACKGROUND: Premature atrial contractions (PACs) are independently associated with atrial fibrillation, stroke, and heart ...
Please provide your email address to receive an email when new articles are posted on . Cognitive decline is one of the potential adverse effects of cranial radiation therapy in cancer patients. It ...
Memantine is approved to treat moderate to severe Alzheimer's disease and other dementias. Evidence suggests that it might also be useful with bipolar disorder, depression, schizophrenia and much more ...
Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...
October 2, 2008 (Salt Lake City, Utah) — New trial data suggest that a large 28-mg, once-daily dose of memantine (Namenda, Axura, Forest Pharmaceuticals) in an extended-release formulation may be an ...
August 27, 2010 — A new study provides more evidence that patients with dementia with Lewy bodies (DLB) may derive some benefit from memantine, an N-methyl-D-aspartate (receptor antagonist already ...
Chilukuri et al 1 have composed an excellent review of pharmacologic interventions for reduction of neurocognitive deficits following radiation to the brain. We strongly agree with the conclusions of ...
(HealthDay News) — The combination of memantine plus sertraline is efficacious for major depressive disorder, according to a study published in the Journal of Clinical Pharmacy and Therapeutics.
The drug memantine can benefit patients with moderate to severe Alzheimer's disease, according to a study reported in the April 3 New England Journal of Medicine. The use of memantine for Alzheimer's ...
There is no scientific proof that patients with moderate or severe Alzheimer's disease benefit from drugs containing the agent memantine, according to a new report. There is no scientific proof that ...
The Food and Drug Administration approved the German medication memantine today to help ease the severe symptoms of an estimated 1 million Americans who suffer from the late stages of Alzheimer's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results